Norway· NO-ID_F27AD694-6AAD-44E6-864B-8DC319854809
Synagis
A palivizumab product containing palivizumab, registered in Norway by AstraZeneca AB (2). The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Palivizumab is registered in 13 of 19 countries.
Countries holding a registration under ATC J06BD01 (palivizumab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Palivizumab · ATC J06BD01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of palivizumab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Palivizumab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$51.40
The record
At a glance
FEST (Norway)- Active substance
- Palivizumab
- Manufacturer
- AstraZeneca AB (2)
- Country
- Norway (NO)
- ATC code
- J06BD01
- ATC class
- Palivizumab
- Defined daily dose
- 3.75 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_F27AD694-6AAD-44E6-864B-8DC319854809
- no_varenummer4296040.5NOK 5262.6
- gtin5000456066839
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSYNAGISAstraZeneca AB, Södertälje
- BelgiumSynagis 100 mg/mlAstraZeneca
- SpainSYNAGIS 100 mg/1 ml SOLUCION INYECTABLEAstrazeneca Ab
- SwitzerlandSynagis 100 mg/1 ml, InjektionslösungAstraZeneca AG
- SwedenSynagis 100 mg/1 ml Injektionsvätska, lösningAstraZeneca AB
- IcelandSynagisAstraZeneca AB*
- PolandSynagisAstraZeneca AB
- FinlandSynagisOrifarm Oy
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d350ae67-563f-4f62-9a97-ac4cbc5e59ba GET /v1/drugs/d350ae67-563f-4f62-9a97-ac4cbc5e59ba?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Palivizumab",
"merkevare_id": "ID_F27AD694-6AAD-44E6-864B-8DC319854809",
"name_form_strength": "Synagis inj, oppl 50 mg/0,5 ml",
"prescription_group": "C"
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.